Priority Review in Merkel Cell Carcinoma, Breakthrough Designation in RET-Altered Cancers, and More
3 ビュー
• 07/17/23
0
0
埋め込む
administrator
加入者
Gina Columbus reports on a priority review designation in Merkel cell carcinoma, a breakthrough therapy designation in select RET-altered cancers, an application submitted in pediatric ALL, and European approvals in multiple myeloma, melanoma, and ALL.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント